Sensus Healthcare, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
February 08, 2024 at 04:16 pm EST
Share
Sensus Healthcare, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported sales was USD 12.57 million compared to USD 13.11 million a year ago. Net income was USD 4.21 million compared to USD 2.83 million a year ago. Basic earnings per share from continuing operations was USD 0.26 compared to USD 0.17 a year ago. Diluted earnings per share from continuing operations was USD 0.26 compared to USD 0.17 a year ago.
For the full year, sales was USD 24.41 million compared to USD 44.53 million a year ago. Net income was USD 0.485 million compared to USD 24.24 million a year ago. Basic earnings per share from continuing operations was USD 0.03 compared to USD 1.47 a year ago. Diluted earnings per share from continuing operations was USD 0.03 compared to USD 1.46 a year ago.
Sensus Healthcare, Inc. is a medical device company. The Company is focused on providing non-invasive treatments for both oncological and non-oncological skin conditions. The Company uses a low-energy X-ray technology known as superficial radiation therapy (SRT). The Company incorporated SRT into its portfolio of treatment devices: the SRT-100, SRT-100+ and SRT-100 Vision. SRT-100, is a photon x-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers and other skin conditions such as keloids. The SRT-100 Vision provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. Its SRT-100+ offer remote diagnostics solutions, including operation tracking.